An upregulation trend of INSIG1 was also seen in cediranib-resistant NSCLC (Supplementary Figure S1D), BV-resistant colon cancer (Supplementary Figure S1E), and BV non-responding CRC (Supplementary Figure S1F). Here, INSIG1 is linked to malignant colon neoplasm.